Comparative Pharmacology
Head-to-head clinical analysis: CEFDINIR versus VELOSEF 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFDINIR versus VELOSEF 250.
CEFDINIR vs VELOSEF '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefdinir is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
Bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
300 mg orally twice daily for 5-10 days, or 600 mg orally once daily for 10 days.
250 mg orally every 6 hours for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life: 1.7 ± 0.6 hours (range 1.4-2.3 h) in healthy adults; prolonged in renal impairment (e.g., up to 8 hours in end-stage renal disease).
Clinical Note
moderateCefdinir + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefdinir."
Clinical Note
moderateIron sucrose + Cefdinir
"The serum concentration of Cefdinir can be decreased when it is combined with Iron sucrose."
Clinical Note
moderateIron + Cefdinir
"The serum concentration of Cefdinir can be decreased when it is combined with Iron."
Clinical Note
moderateFerric pyrophosphate + Cefdinir
1.2-1.5 hours in normal renal function; prolonged in renal impairment (up to 10-20 hours in ESRD)
Renal: 90-95% unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal: <1% biliary, <5% fecal.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); remainder biliary/fecal (<10%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The serum concentration of Cefdinir can be decreased when it is combined with Ferric pyrophosphate."